| Literature DB >> 8295985 |
R E Tjho-Heslinga1, H M Kakebeeke-Kemme, J Davelaar, H de Vroome, J C Bleeker, J A Oosterhuis, J W Leer.
Abstract
The follow-up results are presented for the radiotherapeutic treatment of 49 patients with uveal eye melanoma using ruthenium-106 (106Ru/106Rh) applicators. Graded doses were applied and the degree of regression was found to be correlated with the dose at the top of the tumour. Complete regression is found in 66% of the patients treated with a top dose above 150 Gy, in which case the initial tumour prominence diminishes in about three years to a stable disease or to a flat scar. At this dose a marginal increase in complications was observed as compared with lower dose groups. Useful vision could be preserved in 75% of the eyes.Entities:
Mesh：
Substances：
Year: 1993 PMID： 8295985 DOI： 10.1016/0167-8140(93)90170-d
Source DB: PubMed Journal: Radiother Oncol ISSN： 0167-8140 Impact factor: 6.280